Earlier this month Leidos Inc. was awarded a prime contract with the United States Agency for International Development (USAID). Leidos will provide program support to the Malaria Vaccine Development Program (MVDP). The agreement is a single-award, cost-plus fixed-fee contract lasting five-years at a price of approximately $23.7 million.
“Leidos Life Sciences brings decades of innovation and expertise to this important program, and we are honored to have been selected to provide services and support to USAID and the medical community in their efforts to develop a more effective malaria vaccine,” Said Jerry Hogge, president of Leidos’ Health and Deputy group.
Leidos will provide a series of research and development programs through the USAID. Leidos’ primary responsibilities include vaccine development and program implementation.